{
    "id": 50749,
    "name": "peripheral T-cell lymphoma",
    "source": "DOID",
    "definition": "A mature T-cell and NK-cell lymphoma includes a group of T-cell lymphomas that develop away from the thymus. [url:http\\://en.wikipedia.org/wiki/Peripheral_T-cell_lymphoma]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:0050749",
    "evidence": [
        {
            "id": 3602,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In clinical trials that supported FDA approval, treatment with Beleodaq (belinostat) resulted in an objective response rate of 25.8% (31/120) and a median overall survival of 7.9 months in patients with peripheral T-cell lymphoma (PMID: 26101246).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1078,
                "therapyName": "Belinostat",
                "synonyms": null
            },
            "indication": {
                "id": 50749,
                "name": "peripheral T-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3877,
                    "pubMedId": 26101246,
                    "title": "Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26101246"
                },
                {
                    "id": 15603,
                    "pubMedId": null,
                    "title": "Beleodaq (belinostat) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206256"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3965,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Chidamide (CS055) demonstrated a 28% (22/79) overall response rate in refractory peripheral T-cell lymphoma patients (PMID: 26105599).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3003,
                "therapyName": "Chidamide",
                "synonyms": null
            },
            "indication": {
                "id": 50749,
                "name": "peripheral T-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4313,
                    "pubMedId": 26105599,
                    "title": "Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26105599"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5131,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Aliqopa (copanlisib) treatment resulted in partial response in 50% (2/4) of patients with peripheral T-cell lymphoma (PMID: 24852792).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 995,
                "therapyName": "Copanlisib",
                "synonyms": null
            },
            "indication": {
                "id": 50749,
                "name": "peripheral T-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4879,
                    "pubMedId": 24852792,
                    "title": "Preliminary results of a phase II study of single agent Bay 80-6946, a Novel PI3K inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24852792"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11085,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ALRN-6924 treatment in a patient with peripheral T-cell lymphoma resulted in a complete response (J Clin Oncol 35, 2017 (suppl; abstr 2505)).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 2273,
                "therapyName": "ALRN-6924",
                "synonyms": null
            },
            "indication": {
                "id": 50749,
                "name": "peripheral T-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9071,
                    "pubMedId": null,
                    "title": "Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas",
                    "url": "http://abstracts.asco.org/199/AbstView_199_187803.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11790,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Fenretinide treatment resulted in complete response in 17% (2/11), partial response in 17% (2/11), and stable disease in 42% (5/11) of patients with peripheral T-cell lymphoma (PMID:28420721).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2731,
                "therapyName": "Fenretinide",
                "synonyms": null
            },
            "indication": {
                "id": 50749,
                "name": "peripheral T-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9767,
                    "pubMedId": 28420721,
                    "title": "Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28420721"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14005,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Copiktra (duvelisib) treatment resulted in an overall response rate of 50% (8/16, 3 complete response, 5 partial response) with a median duration of treatment of 11.3 weeks in patients with peripheral T-cell lymphoma (PMID: 29233821; NCT01476657).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1024,
                "therapyName": "Duvelisib",
                "synonyms": null
            },
            "indication": {
                "id": 50749,
                "name": "peripheral T-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11408,
                    "pubMedId": 29233821,
                    "title": "Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29233821"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15228,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (ECHELON-2) that supported FDA approval, treatment with Adcentris (brentuximab vedotin) in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) resulted in improved median progression-free survival (48.2 vs 20.8 months, HR=0.71, p=0.011) compared to standard chemotherapy in patients with previously untreated TNFRSF8 (CD30)-positive peripheral T-cell lymphoma, 75% of the patients were diagnosed with systemic anaplastic large cell lymphoma (PMID: 30522922; NCT01777152).",
            "molecularProfile": {
                "id": 23635,
                "profileName": "TNFRSF8 positive"
            },
            "therapy": {
                "id": 7500,
                "therapyName": "Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Prednisone",
                "synonyms": null
            },
            "indication": {
                "id": 50749,
                "name": "peripheral T-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15061,
                    "pubMedId": 30522922,
                    "title": "Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30522922"
                },
                {
                    "id": 15574,
                    "pubMedId": null,
                    "title": "Adcetris (brentuximab vedotin) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125388"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18892,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Adcentris (brentuximab vedotin) in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) is included in guidelines as preferred first-line therapy and subsequent therapy for patients with TNFRSF8 (CD30)-positive peripheral T-cell lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 23635,
                "profileName": "TNFRSF8 positive"
            },
            "therapy": {
                "id": 7500,
                "therapyName": "Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Prednisone",
                "synonyms": null
            },
            "indication": {
                "id": 50749,
                "name": "peripheral T-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18894,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Adcentris (brentuximab vedotin) is included in guidelines as a preferred second-line and subsequent therapy for patients with TNFRSF8 (CD30)-positive peripheral T-cell lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 23635,
                "profileName": "TNFRSF8 positive"
            },
            "therapy": {
                "id": 2486,
                "therapyName": "Brentuximab vedotin",
                "synonyms": null
            },
            "indication": {
                "id": 50749,
                "name": "peripheral T-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19565,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CD4CAR-expressing natural killer cells induced tumor cell lysis when co-cultured with a CD4-positive peripheral T-cell lymphoma cell line in culture, and reduced tumor burden and increased survival in a cell line xenograft model (PMID: 29348865).",
            "molecularProfile": {
                "id": 34220,
                "profileName": "CD4 positive"
            },
            "therapy": {
                "id": 9084,
                "therapyName": "CD4CAR",
                "synonyms": null
            },
            "indication": {
                "id": 50749,
                "name": "peripheral T-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17177,
                    "pubMedId": 29348865,
                    "title": "Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29348865"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01431209",
            "title": "Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 907,
                    "therapyName": "Ruxolitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01644253",
            "title": "Phase 1b Safety and Efficacy Study of TRU-016",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4745,
                    "therapyName": "Idelalisib + Otlertuzumab + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 4742,
                    "therapyName": "Otlertuzumab + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 4743,
                    "therapyName": "Obinutuzumab + Otlertuzumab",
                    "synonyms": null
                },
                {
                    "id": 4744,
                    "therapyName": "Ibrutinib + Otlertuzumab",
                    "synonyms": null
                },
                {
                    "id": 8256,
                    "therapyName": "Bendamustine + Otlertuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02181218",
            "title": "Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1476,
                    "therapyName": "Pegfilgrastim",
                    "synonyms": null
                },
                {
                    "id": 1075,
                    "therapyName": "Romidepsin",
                    "synonyms": null
                },
                {
                    "id": 1611,
                    "therapyName": "Dexamethasone + Gemcitabine + Oxaliplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02232516",
            "title": "Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8060,
                    "therapyName": "Lenalidomide + Romidepsin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02273739",
            "title": "Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2982,
                    "therapyName": "Enasidenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02440685",
            "title": "A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 7391,
                    "therapyName": "ASN002",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02464228",
            "title": "Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 938,
                    "therapyName": "Tipifarnib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02495415",
            "title": "Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2731,
                    "therapyName": "Fenretinide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02512497",
            "title": "Romidepsin Maintenance After Allogeneic Stem Cell Transplantation",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1075,
                    "therapyName": "Romidepsin",
                    "synonyms": null
                },
                {
                    "id": 8058,
                    "therapyName": "Busulfan + Fludarabine + Romidepsin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02520791",
            "title": "Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4762,
                    "therapyName": "MEDI-570",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02535247",
            "title": "Study of MK-3475 in Relapsed or Refractory Peripheral T-cell Non-Hodgkin Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02567656",
            "title": "Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2020,
                    "therapyName": "RP6530",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02576496",
            "title": "Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6104,
                    "therapyName": "Tinostamustine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02581631",
            "title": "A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3263,
                    "therapyName": "Brentuximab vedotin + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02689453",
            "title": "Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9641,
                    "therapyName": "Alemtuzumab + rhIL-15",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02797470",
            "title": "Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9777,
                    "therapyName": "Carmustine + CCR5 shRNA/TRIM5a/TAR decoy-transduced CD34+ HPCs + Cytarabine + Etoposide + Melphalan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02875002",
            "title": "Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 4826,
                    "therapyName": "Belinostat + Volasertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02978625",
            "title": "Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 5080,
                    "therapyName": "Nivolumab + Talimogene laherparepvec",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03011814",
            "title": "Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 3934,
                    "therapyName": "Durvalumab + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03017820",
            "title": "VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7269,
                    "therapyName": "VSV-hIFNbeta-NIS",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03049449",
            "title": "T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9020,
                    "therapyName": "ATLCAR.CD30 cells",
                    "synonyms": null
                },
                {
                    "id": 2291,
                    "therapyName": "Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03075553",
            "title": "Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03161223",
            "title": "Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5882,
                    "therapyName": "Durvalumab + Romidepsin",
                    "synonyms": null
                },
                {
                    "id": 4178,
                    "therapyName": "Azacitidine + Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 5881,
                    "therapyName": "Azacitidine + Durvalumab + Romidepsin",
                    "synonyms": null
                },
                {
                    "id": 5880,
                    "therapyName": "Durvalumab + Pralatrexate + Romidepsin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03218683",
            "title": "Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies.",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6425,
                    "therapyName": "AZD5991",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03240211",
            "title": "Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6356,
                    "therapyName": "Pembrolizumab + Pralatrexate",
                    "synonyms": null
                },
                {
                    "id": 6355,
                    "therapyName": "Decitabine + Pembrolizumab + Pralatrexate",
                    "synonyms": null
                },
                {
                    "id": 5127,
                    "therapyName": "Decitabine + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03264131",
            "title": "BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9023,
                    "therapyName": "Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03278782",
            "title": "Study of Pembrolizumab (MK-3475) in Combination With Romidepsin",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1075,
                    "therapyName": "Romidepsin",
                    "synonyms": null
                },
                {
                    "id": 5728,
                    "therapyName": "Pembrolizumab + Romidepsin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03328104",
            "title": "AflacLL1602 ENCERT",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8014,
                    "therapyName": "Cyclophosphamide + Etoposide + Everolimus + Nelarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03372057",
            "title": "A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1024,
                    "therapyName": "Duvelisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03409432",
            "title": "Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9024,
                    "therapyName": "Brentuximab vedotin + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03534180",
            "title": "Venetoclax in Treating Participants With Recurrent or Refractory Mature T-Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1562,
                    "therapyName": "Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03547700",
            "title": "Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8066,
                    "therapyName": "Ixazomib + Romidepsin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03586999",
            "title": "Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7928,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Etoposide + Nivolumab + Prednisone + Vincristine",
                    "synonyms": "Nivolumab + EPOCH"
                }
            ]
        },
        {
            "nctId": "NCT03598998",
            "title": "Pembrolizumab and Pralatrexate in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphomas",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6356,
                    "therapyName": "Pembrolizumab + Pralatrexate",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03601819",
            "title": "Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2006,
                    "therapyName": "Pacritinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03674411",
            "title": "Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9613,
                    "therapyName": "Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus",
                    "synonyms": null
                },
                {
                    "id": 9612,
                    "therapyName": "Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03829540",
            "title": "CD4CAR for CD4+ Leukemia and Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9084,
                    "therapyName": "CD4CAR",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03902184",
            "title": "IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (TELLOMAK)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8662,
                    "therapyName": "Gemcitabine + IPH4102 + Oxaliplatin",
                    "synonyms": null
                },
                {
                    "id": 8650,
                    "therapyName": "IPH4102",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03905135",
            "title": "Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8142,
                    "therapyName": "Avelumab + rhIL-15",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03921879",
            "title": "Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9568,
                    "therapyName": "OT-82",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03927105",
            "title": "Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6438,
                    "therapyName": "Cabiralizumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03947255",
            "title": "A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2486,
                    "therapyName": "Brentuximab vedotin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04074746",
            "title": "Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 8710,
                    "therapyName": "AFM13 + Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04083495",
            "title": "CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9020,
                    "therapyName": "ATLCAR.CD30 cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04101331",
            "title": "Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4389,
                    "therapyName": "AFM13",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04234048",
            "title": "Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 2731,
                    "therapyName": "Fenretinide",
                    "synonyms": null
                }
            ]
        }
    ]
}